ReviewThe oncologist2013
Genomics of squamous cell lung cancer.
Review in The oncologist, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- A pragmatic workflow for advanced NSCLC diagnosis in routine practice: Integrating histopathology, PD-L1 scoring, and EGFR testing.Lung India : official organ of Indian Chest Society · 2026Article
- Gene amplification in the premalignant stages of non-small cell lung cancer development.Frontiers in oncology · 2026Review
- Molecular and immune characterization of Chinese early-stage non-squamous non-small cell lung cancer: a multi-omics cohort study.Translational lung cancer research · 2024Article
- Brief Report: Prognostic Relevance of 3q Amplification in Squamous Cell Carcinoma of the Lung.JTO clinical and research reports · 2023Article
- Heterogeneous pattern of gene expression driven byFrontiers in oncology · 2023Article
- Molecular Pathology of Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- Partial EMT in Squamous Cell Carcinoma: A Snapshot.International journal of biological sciences · 2021Review
- Downregulation of miRNA-126-3p is associated with progression of and poor prognosis for lung squamous cell carcinoma.FEBS open bio · 2020Article
- ZWINT is the next potential target for lung cancer therapy.Journal of cancer research and clinical oncology · 2019Article
- Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.Cancers · 2018Review
- Expression ratio of the TGFβ-inducible gene MYO10 is prognostic for overall survival of squamous cell lung cancer patients and predicts chemotherapy response.Scientific reports · 2018Article
- Article
- Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Article
- Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Article
- Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma.BMC cancer · 2015Article
- Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer.Expert review of molecular diagnostics · 2015Review
- Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.Translational lung cancer research · 2015Review
- Novel candidate key drivers in the integrative network of genes, microRNAs, methylations, and copy number variations in squamous cell lung carcinoma.BioMed research international · 2015Article
- Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types.Cell cycle (Georgetown, Tex.) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 30% of patients with non-small cell lung cancer have the squamous cell carcinoma (SQCC) histological subtype. Although targeted therapies have improved outcomes in patients with adenocarcinoma, no agents are currently approved specifically for use in SQCC. The Cancer Genome Atlas (TCGA) recently published the results of comprehensive genomic analyses of tumor samples from 178 patients with SQCC of the lung. In this review, we briefly discuss key molecular aberrations reported by TCGA and other investigators and their potential therapeutic implications. Carefully designed preclinical and clinical studies based on these large-scale genomic analyses are critical to improve the outcomes of patients with SQCC of lung in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.